Vol.56 No.1 January 2008
Antibacterial activity of gemifloxacin against clinical isolates
1)Department of Infection Control Science, Postgraduate Course, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan
2)Department of Bacteriology, Juntendo University School of Medicine
3)Department of Bacteriology, Koto-Biken Medical Laboratories
4)Clinical Laboratory, Juntendo University Hospital
5)Department of Laboratory Medicine, Juntendo University School of Medicine
6)Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc.
Abstract
In vitro antibacterial activity of gemifloxacin, a new fluoro quinolone agent, and other drugs was determined against clinical isolates in 2005 Japan and clinical isolates of levofloxacin-resistant Streptococcus pneumoniae after 2003.
Gemifloxacin MIC90 was 0.031 μg/mL, higher than other fluoro quinolone agents. Gemifloxacin activity is good in levofloxacin-resistant S. pneumoniae because gemifloxacin MIC90 of levofloxacin-resistant Streptococcus pneumoniae was 0.5 μg/mL, higher than other fluoro quinolone agents. Gemifloxacin MIC90 against Haemophilus influenzae was 0.015 μg/mL. Gemifloxacin MIC90 against ampicillin-resistant β-lactamase negative Haemophilus influenzae (BLNAR) was 0.063 μg/mL. Gemifloxacin MIC90 against methicillin-resistant Staphylococcus aureus was low the same as for other fluoro quinolone agents. Gemifloxacin activity was shown in Moraxella (Branhamella) catarrhalis, Klebsiella pneumoniae, and Pseudomonas aeruginosa similar to other fluoro-quinolone agents. Our results suggest that gemifloxacin effective clinical respiratory organ infectious disease treatment.
Key word
gemifloxacin, respiratory quinolone, Streptococcus pneumoniae, BLNAR (beta-lactamase nonproducing ampicillin resistant)
Received
July 20, 2007
Accepted
November 16, 2007
Jpn. J. Chemother. 56 (1): 16-20, 2008
